These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3516477)

  • 1. Pantethine improves the lipid abnormalities of chronic hemodialysis patients: results of a multicenter clinical trial.
    Donati C; Barbi G; Cairo G; Prati GF; Degli Esposti E
    Clin Nephrol; 1986 Feb; 25(2):70-4. PubMed ID: 3516477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of long-term treatment with pantethine in patients with dyslipidemia.
    Arsenio L; Bodria P; Magnati G; Strata A; Trovato R
    Clin Ther; 1986; 8(5):537-45. PubMed ID: 3094958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of pantethine in dyslipidemia of chronic uremic patients under dialysis treatment].
    Bergesio F; Ciuti R; Innocenti D; Galli GA; Frizzi V
    G Clin Med; 1985; 66(11-12):433-40. PubMed ID: 3835087
    [No Abstract]   [Full Text] [Related]  

  • 4. [A double-blind clinical trial--the effects of pantethine on serum lipids in patients with hyperlipidemia].
    Lu ZL
    Zhonghua Xin Xue Guan Bing Za Zhi; 1989 Aug; 17(4):221-3. PubMed ID: 2697544
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical use of pantethine by parenteral route in the treatment of hyperlipidemia].
    Arsenio L; Bodria P; Bossi S; Lateana M; Strata A
    Acta Biomed Ateneo Parmense; 1987; 58(5-6):143-52. PubMed ID: 2970754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children.
    Bertolini S; Donati C; Elicio N; Daga A; Cuzzolaro S; Marcenaro A; Saturnino M; Balestreri R
    Int J Clin Pharmacol Ther Toxicol; 1986 Nov; 24(11):630-7. PubMed ID: 3098691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the cholesterol-lowering effectiveness of pantethine in women in perimenopausal age].
    Binaghi P; Cellina G; Lo Cicero G; Bruschi F; Porcaro E; Penotti M
    Minerva Med; 1990 Jun; 81(6):475-9. PubMed ID: 2359503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lowering effect of pantethine on plasma beta-thromboglobulin and lipids in diabetes mellitus.
    Eto M; Watanabe K; Chonan N; Ishii K
    Artery; 1987; 15(1):1-12. PubMed ID: 2963604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients].
    Donati C; Bertieri RS; Barbi G
    Clin Ter; 1989 Mar; 128(6):411-22. PubMed ID: 2524328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in fatty acid composition of the single platelet phospholipids induced by pantethine treatment.
    Gensini GF; Prisco D; Rogasi PG; Matucci M; Neri Serneri GG
    Int J Clin Pharmacol Res; 1985; 5(5):309-18. PubMed ID: 4066081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of the lipotropic activity of the preparation Fosfolip].
    Ligas B; Proietti C; Chiti D
    Minerva Med; 1983 Apr; 74(14-15):835-8. PubMed ID: 6340000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of coenzyme A vs pantethine for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study.
    Chen YQ; Zhao SP; Zhao YH
    J Clin Lipidol; 2015; 9(5):692-7. PubMed ID: 26350816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of pantethine therapy in chronic uremic patients undergoing hemodialysis with type IV hyperlipoproteinemia].
    Seghieri G; Maffucci G; Toscano G; Santoni F; Tuci S; De Giorgio LA
    G Clin Med; 1985; 66(5-6):187-92. PubMed ID: 4065470
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hyperlipidemia, diabetes and atherosclerosis: efficacy of treatment with pantethine].
    Arsenio L; Caronna S; Lateana M; Magnati G; Strata A; Zammarchi G
    Acta Biomed Ateneo Parmense; 1984; 55(1):25-42. PubMed ID: 6232801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidemia in patients with chronic renal failure and in renal transplant patients.
    Shah B; Nair S; Sirsat RA; Ashavaid TF; Nair KG
    J Postgrad Med; 1994; 40(2):57-60. PubMed ID: 8737552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients.
    Rodríguez-Ferrero ML; Anaya F
    Transplant Proc; 2008 Dec; 40(10):3492-5. PubMed ID: 19100421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of pantethine on blood lipids].
    Giannini SD; Forti N; Di Rienzo F; Campanari JC; Ziliotto EE
    Arq Bras Cardiol; 1986 Apr; 46(4):283-9. PubMed ID: 3548666
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
    Chen ST; Ferng SH; Yang CS; Peng SJ; Lee HR; Chen JR
    Am J Kidney Dis; 2005 Dec; 46(6):1099-106. PubMed ID: 16310576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.